Life Sciences Companies

Optimize Your Biomarker Product Portfolio

Whether you want to select the most promising biomarkers or best suited indications/diseases, benchmark competitors or manage your product pipeline and portfolio: evidence-based decision making is key to meeting your targets.

Minimizing Risk in Pharmaceutical R&D

Our unique L-Matrix Method, in combination with our exclusive L&C database, allows us to analyze an unequaled amount of biomedical literature in a quality-controlled, unbiased approach:

  • thousands of study publications (preclinical and clinical, human and/or animal models)
  • > 80 indications
  • up to 300 data points per study

The highly customized reports deliver graphical visualization of complex relations, e.g. the impact of inclusion/exclusion criteria on biomarker performance and intended-use labeling.

Our Services for Evidence-Based Decision Making in Biomarker R&D